MMS, a Canton Township-based clinical research organization, has acquired Exploristics, a biostatistics and data science company based in Belfast, Northern Ireland. Terms of the transaction were not disclosed.
The acquisition will add Exploristics’ flagship product, KerusCloud, a state-of-the-art, cloud-based statistical modeling and simulation platform to MMS’ data-driven approach toward efficient drug development.
It is expected to solidify MMS’s position as the leader in biometrics and development strategy solutions for biotechnology and pharmaceutical sponsors of all sizes.
“When exploring acquisition opportunities to enhance our strategic capabilities as a leading data CRO, we sought organizations that would complement our existing regulatory approach and build a powerful combination of regulatory and statistical design expertise, combined with market-leading study simulation software,” says Uma Sharma, CEO of MMS. “We found that in Exploristics, along with a like-minded culture.”
Chris Schoonmaker, COO at MMS, adds, “Exploristics joining MMS is an exceptional fit, and we look forward to delivering even greater value to our clients through optimized strategies that reduce the overall time and cost burden in drug development.”
The Exploristics acquisition aligns with MMS’s focus on broadening its data-focused solutions to enhance its ability to simulate, analyze, and optimize studies, as well as reduce risk and drive efficiencies. By combining the two organizations’ strengths, MMS will now provide:
- Advanced statistical design and data science capabilities across diverse therapeutic areas and study types.
- Enhanced and real-time pivots for orphan, rare, and special disease populations with an unmet medical need.
- Study simulation and development planning with the integration of KerusCloud into an existing award-winning technology suite that boasts a 3x increase in development program success rates and up to USD 20 million saved on a single study.
- Expanded global presence, with increased scale in Europe and access to a highly skilled team of biostatisticians and data scientists.
“Joining MMS represents an exciting new chapter for Exploristics,” says Aiden Flynn, founder and CEO of Exploristics, now senior vice president and head of strategic statistical consulting at MMS. “Our ethos has always centered on openness, honesty, professionalism, flexibility, and creativity — qualities that I’ve experienced at MMS since day one of our discussions. I am confident that our employees, partners, and clients will benefit from this partnership as we amplify our impact and expand our global reach.”
Ben Dudley, chief commercial officer at MMS, adds, “Our presence in Europe has seen significant growth in recent years, and this acquisition adds to our vitality in the region. Our focus on data for better trial data execution, lower risk, stronger submissions, integration of real-world data into clinical outputs and accelerated outcomes has never been stronger than it is today.”
For more information, visit mmsholdings.com.
